Protalix BioTherapeutics

A biopharmaceutical company developing plant cell-expressed enzyme replacement therapies for rare lysosomal storage disorders.

Health Tech & Life Sciences
public
Public Hackensack, United States Founded 1993
Last updated 2026-11-10
Total raised
$159.9M
Last: Public Offering 2021-02
Stage
Public
Founded
1993
Headcount
230
HQ
Hackensack, United States
Sector
Health Tech & Life Sciences

About

Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. The company is advancing promising candidates leveraging its expertise in protein therapeutics through its proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as its chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, Protalix is committed to expanding its pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.

Funding history · 9 rounds · $159.9M total

9 events/rounds · $159.9M Total Funding: $71.0M in Private Equity, $75.0M in Public Equity
Mar 2025
Public Offering $20.0M EDGAR filing SEC-EDGAR 8-K
Jul 2021
Public Offering $20.0M EDGAR filing SEC-EDGAR 424B5
Oct 2020
Public Offering $35.0M EDGAR filing SEC-EDGAR 8-K
Mar 2020
PIPE $43.7M EDGAR filing SEC-EDGAR 8-K
Mar 2011
D Round $22.0M globes.co.il ↗
Apr 2008
Grant Undisclosed prior (startupim db)
Dec 2006
Public Offering Undisclosed wikipedia.org
Oct 2004
Grant $6.0M biospace.com

Offices

Hackensack, United States · HQ / main office

Q&A

What is Protalix BioTherapeutics' primary focus?
Protalix BioTherapeutics is a biopharmaceutical company that develops plant cell-expressed enzyme replacement therapies for rare lysosomal storage disorders.
When was Protalix BioTherapeutics founded?
Protalix BioTherapeutics was founded in 1993.
What is Protalix BioTherapeutics' current employee count?
Protalix BioTherapeutics has 201-500 employees.
What was Protalix BioTherapeutics' most recent public offering?
In March 2025, Protalix BioTherapeutics had a Public Offering that raised $20,000,000.
Which investors participated in Protalix BioTherapeutics' C Round in July 2005?
Protalix BioTherapeutics' C Round in July 2005 included investments from Phillip Frost.
What was the amount raised in Protalix BioTherapeutics' PIPE round in March 2020?
In March 2020, Protalix BioTherapeutics raised $43,700,000 in a PIPE round.
Who is the current President & Chief Executive Officer of Protalix BioTherapeutics?
Moshe Manor serves as the President & Chief Executive Officer of Protalix BioTherapeutics.
What is Protalix BioTherapeutics' proprietary technology for protein expression?
Protalix BioTherapeutics utilizes its proprietary, commercial-scale ProCellEx® plant cell-based protein expression system for protein therapeutics.

Team · 15

Yoseph Shaaltiel
Founder · Board Member & Vice President, Research and Development
Moshe Manor
President & Chief Executive Officer
Gilad Mamlok
Senior Vice President & Chief Financial Officer
Yaron Naos
Senior Vice President, Operations
Ori Kalid
Vice President, Research and Development
Shoshi Tessler
Vice President, Clinical Development & Regulatory Affairs
Tanya Gershanik
Vice President, Quality Affairs
Yael Fellous
Vice President, Human Resources
Eliot Forster
Chairman of the Board of Directors
Amos Bar Shalev
Director
Shmuel “Muli” Ben Zvi
Director
Pol F. Boudes
Director
Christian Elze
Director
Gwen Melincoff
Director
Aharon Schwartz
Director

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers

Highlights

Patents

Tags

antibodiesoral-drugspharmaceuticalsproteinsgenetic-disordersplant-proteininflammatory-diseasespharma-companiesdrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteprotalix.com
LinkedInlinkedin.com/company/739969
X / Twittertwitter.com/protalix_bio
Wikipediaen.wikipedia.org/wiki/Protalix_BioTherapeutics
Wikidatawikidata.org/wiki/Q7251166

Identifiers & details

Legal nameProtalix BioTherapeutics Inc.
Founded1993
Employees (exact)230
Wikidata QIDQ7251166

Radar intelligence

Web history (Wayback)

Domainprotalix.com

Wikidata

QIDQ7251166

Certificate / subdomain footprint

Subdomains8

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)511903288
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated1993-12-27
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens1
Registry events3 — people (2), charge (1)
Registered addressסנונית 2 כרמיאל

Recent registry events

DateEvent
2025-11-24עדכון דירקטורים-הסרת דירקטור
2025-11-24עדכון דירקטורים-הוספת דירקטור
2025-12-17רישום שעבוד